Ropes and Gray: Teva and Samsung Enter License and Commercialization Agreement for Two FDA-Approved Biosimilars in the U.S.
November 04, 2026
November 04, 2026
BOSTON, Massachusetts, Nov. 4 -- Ropes and Gray, a law firm, issued the following news:
* * *
Teva and Samsung Enter License and Commercialization Agreement for Two FDA-Approved Biosimilars in the U.S.
November 3, 2026
Ropes & Gray advised Teva Pharmaceutical Industries in a licensing and commercialization agreement with Samsung Bioepis that would give Teva U.S. rights to two FDA-approved immunology biosimilars, infliximab-abda and etanerce . . .
* * *
Teva and Samsung Enter License and Commercialization Agreement for Two FDA-Approved Biosimilars in the U.S.
November 3, 2026
Ropes & Gray advised Teva Pharmaceutical Industries in a licensing and commercialization agreement with Samsung Bioepis that would give Teva U.S. rights to two FDA-approved immunology biosimilars, infliximab-abda and etanerce . . .
